FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891898023> ?p ?o ?g. }

• W2891898023 endingPage "1182.e5" @default.
• W2891898023 startingPage "1176" @default.
• W2891898023 abstract "BackgroundVirus-associated febrile lower respiratory tract infections (fLRIs) during infancy have been identified as risk factors for persistent wheeze development. We hypothesized that variations in innate immune defense capacity during this period, as exemplified by production of type 1 and 3 interferons (T1/3IFNs), might be an underlying determinant of risk.ObjectiveWe sought to investigate relationships between postnatal development of innate interferon response capacity and susceptibility to early infections and persistent wheeze.MethodsWe studied a subset of subjects from a birth cohort at high risk for asthma/allergy and determined the capacity of cord blood cells (n = 151) to produce any of a panel of 17 T1/3IFNs in response to the viral mimic polyinosinic-polycytidylic acid using a sensitive PCR assay. We investigated relationships between neonatal interferon responses and lower respiratory tract infection history during infancy, wheezing history to 5 age years, and ensuing maturation of innate immune capacity by age 4 years (n = 160) and 10 years (n = 125).ResultsAlthough cohort subjects produced an average of 2.6 ± 0.3 of the 17 innate interferons tested at birth, 24% showed no T1/3IFN production. This nonproducer subgroup showed increased risk for infant fLRIs (odds ratio, 2.62; 95% CI, 1.14-6.06; P = .024) and persistent wheeze (odds ratio, 4.24; 95% CI, 1.60-11.24; P = .004) at age 5 years relative to those producing 1 or more T1/3IFNs, whereas risk for infant wheezy lower respiratory tract infections or “transient early wheeze” was unaffected. Moreover, infants who experienced fLRIs subsequently demonstrated accelerated development of T1/3IFN response capacity between 1 and 4 years of age.ConclusionsT1/3IFN response capacity appears strongly developmentally constrained at birth. Infants in whom this negative regulation is strongest manifest increased risk for severe respiratory tract infections during infancy and subsequent persistent wheeze. Virus-associated febrile lower respiratory tract infections (fLRIs) during infancy have been identified as risk factors for persistent wheeze development. We hypothesized that variations in innate immune defense capacity during this period, as exemplified by production of type 1 and 3 interferons (T1/3IFNs), might be an underlying determinant of risk. We sought to investigate relationships between postnatal development of innate interferon response capacity and susceptibility to early infections and persistent wheeze. We studied a subset of subjects from a birth cohort at high risk for asthma/allergy and determined the capacity of cord blood cells (n = 151) to produce any of a panel of 17 T1/3IFNs in response to the viral mimic polyinosinic-polycytidylic acid using a sensitive PCR assay. We investigated relationships between neonatal interferon responses and lower respiratory tract infection history during infancy, wheezing history to 5 age years, and ensuing maturation of innate immune capacity by age 4 years (n = 160) and 10 years (n = 125). Although cohort subjects produced an average of 2.6 ± 0.3 of the 17 innate interferons tested at birth, 24% showed no T1/3IFN production. This nonproducer subgroup showed increased risk for infant fLRIs (odds ratio, 2.62; 95% CI, 1.14-6.06; P = .024) and persistent wheeze (odds ratio, 4.24; 95% CI, 1.60-11.24; P = .004) at age 5 years relative to those producing 1 or more T1/3IFNs, whereas risk for infant wheezy lower respiratory tract infections or “transient early wheeze” was unaffected. Moreover, infants who experienced fLRIs subsequently demonstrated accelerated development of T1/3IFN response capacity between 1 and 4 years of age. T1/3IFN response capacity appears strongly developmentally constrained at birth. Infants in whom this negative regulation is strongest manifest increased risk for severe respiratory tract infections during infancy and subsequent persistent wheeze." @default.
• W2891898023 created "2018-09-27" @default.
• W2891898023 creator A5012144635 @default.
• W2891898023 creator A5017272011 @default.
• W2891898023 creator A5029312666 @default.
• W2891898023 creator A5043139605 @default.
• W2891898023 creator A5046668675 @default.
• W2891898023 creator A5048175603 @default.
• W2891898023 creator A5051078975 @default.
• W2891898023 creator A5053481811 @default.
• W2891898023 creator A5053704352 @default.
• W2891898023 creator A5065605569 @default.
• W2891898023 creator A5082721735 @default.
• W2891898023 creator A5091356015 @default.
• W2891898023 date "2019-03-01" @default.
• W2891898023 modified "2023-10-01" @default.
• W2891898023 title "Developmental regulation of type 1 and type 3 interferon production and risk for infant infections and asthma development" @default.
• W2891898023 cites W1544174173 @default.
• W2891898023 cites W1937469117 @default.
• W2891898023 cites W1973221350 @default.
• W2891898023 cites W1986189079 @default.
• W2891898023 cites W2004068381 @default.
• W2891898023 cites W2005599815 @default.
• W2891898023 cites W2012107292 @default.
• W2891898023 cites W2019472095 @default.
• W2891898023 cites W2025550392 @default.
• W2891898023 cites W2029457187 @default.
• W2891898023 cites W2052633053 @default.
• W2891898023 cites W2057192777 @default.
• W2891898023 cites W2067492674 @default.
• W2891898023 cites W2070416023 @default.
• W2891898023 cites W2086975476 @default.
• W2891898023 cites W2100589529 @default.
• W2891898023 cites W2105087430 @default.
• W2891898023 cites W2110422192 @default.
• W2891898023 cites W2113444773 @default.
• W2891898023 cites W2114570899 @default.
• W2891898023 cites W2120949068 @default.
• W2891898023 cites W2125324778 @default.
• W2891898023 cites W2138824564 @default.
• W2891898023 cites W2157110918 @default.
• W2891898023 cites W2167125750 @default.
• W2891898023 cites W2322654587 @default.
• W2891898023 cites W2591587054 @default.
• W2891898023 doi "https://doi.org/10.1016/j.jaci.2018.08.035" @default.
• W2891898023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30217468" @default.
• W2891898023 hasPublicationYear "2019" @default.
• W2891898023 type Work @default.
• W2891898023 sameAs 2891898023 @default.
• W2891898023 citedByCount "30" @default.
• W2891898023 countsByYear W28918980232019 @default.
• W2891898023 countsByYear W28918980232020 @default.
• W2891898023 countsByYear W28918980232021 @default.
• W2891898023 countsByYear W28918980232022 @default.
• W2891898023 countsByYear W28918980232023 @default.
• W2891898023 crossrefType "journal-article" @default.
• W2891898023 hasAuthorship W2891898023A5012144635 @default.
• W2891898023 hasAuthorship W2891898023A5017272011 @default.
• W2891898023 hasAuthorship W2891898023A5029312666 @default.
• W2891898023 hasAuthorship W2891898023A5043139605 @default.
• W2891898023 hasAuthorship W2891898023A5046668675 @default.
• W2891898023 hasAuthorship W2891898023A5048175603 @default.
• W2891898023 hasAuthorship W2891898023A5051078975 @default.
• W2891898023 hasAuthorship W2891898023A5053481811 @default.
• W2891898023 hasAuthorship W2891898023A5053704352 @default.
• W2891898023 hasAuthorship W2891898023A5065605569 @default.
• W2891898023 hasAuthorship W2891898023A5082721735 @default.
• W2891898023 hasAuthorship W2891898023A5091356015 @default.
• W2891898023 hasConcept C126322002 @default.
• W2891898023 hasConcept C156957248 @default.
• W2891898023 hasConcept C203014093 @default.
• W2891898023 hasConcept C207480886 @default.
• W2891898023 hasConcept C2776012195 @default.
• W2891898023 hasConcept C2776042228 @default.
• W2891898023 hasConcept C2778338976 @default.
• W2891898023 hasConcept C534529494 @default.
• W2891898023 hasConcept C71924100 @default.
• W2891898023 hasConcept C72563966 @default.
• W2891898023 hasConcept C86803240 @default.
• W2891898023 hasConceptScore W2891898023C126322002 @default.
• W2891898023 hasConceptScore W2891898023C156957248 @default.
• W2891898023 hasConceptScore W2891898023C203014093 @default.
• W2891898023 hasConceptScore W2891898023C207480886 @default.
• W2891898023 hasConceptScore W2891898023C2776012195 @default.
• W2891898023 hasConceptScore W2891898023C2776042228 @default.
• W2891898023 hasConceptScore W2891898023C2778338976 @default.
• W2891898023 hasConceptScore W2891898023C534529494 @default.
• W2891898023 hasConceptScore W2891898023C71924100 @default.
• W2891898023 hasConceptScore W2891898023C72563966 @default.
• W2891898023 hasConceptScore W2891898023C86803240 @default.
• W2891898023 hasFunder F4320334705 @default.
• W2891898023 hasIssue "3" @default.
• W2891898023 hasLocation W28918980231 @default.
• W2891898023 hasLocation W28918980232 @default.
• W2891898023 hasOpenAccess W2891898023 @default.
• W2891898023 hasPrimaryLocation W28918980231 @default.
• W2891898023 hasRelatedWork W2030601987 @default.
• W2891898023 hasRelatedWork W2035147639 @default.

• next